SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today a series of events for clinicians attending the 2024 SIR Annual Meeting. These educational events will take place at Merit’s headquarters and at SIR booth 320.
On March 26, Merit will host an Evening of Innovation at its Salt Lake City headquarters from 6:30 p.m.– 9:00 p.m. During the evening, guests will hear from Merit’s Chairman and CEO, Fred Lampropoulos, attend a reception, tour Merit’s manufacturing facility, and learn firsthand about Merit’s history of innovation.
Throughout SIR, Merit will host the following educational events at booth 320:
Register for these educational events.
“We welcome SIR and its members to Salt Lake City, home of Merit’s corporate headquarters and where Merit was founded thirty-seven years ago,” said Mr. Lampropoulos. “As a supporter of SIR, we share the organization’s commitment to educational opportunities and clinical research to advance the practice of interventional radiology. We are excited to share Merit’s full scope of interventional radiology offerings and solutions with this distinguished audience, furthering our mission to improve patient lives."
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$97.13 |
Daily Change: | -1.87 -1.89 |
Daily Volume: | 544,520 |
Market Cap: | US$5.660B |
November 25, 2024 November 01, 2024 October 30, 2024 September 17, 2024 September 16, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB